Role of Renal Drug Exposure in Polymyxin B-Induced Nephrotoxicity

ABSTRACT Despite dose-limiting nephrotoxic potentials, polymyxin B has reemerged as the last line of therapy against multidrug-resistant Gram-negative bacterial infections. However, the handling of polymyxin B by the kidneys is still not thoroughly understood. The objectives of this study were to evaluate the impact of renal polymyxin B exposure on nephrotoxicity and to explore the role of megalin in renal drug accumulation. Sprague-Dawley rats (225 to 250 g) were divided into three dosing groups, and polymyxin B was administered (5 mg/kg, 10 mg/kg, and 20 mg/kg) subcutaneously once daily. The onset of nephrotoxicity over 7 days and renal drug concentrations 24 h after the first dose were assessed. The effects of sodium maleate (400 mg/kg intraperitoneally) on megalin homeostasis were evaluated by determining the urinary megalin concentration and electron microscopic study of renal tissue. The serum/renal pharmacokinetics of polymyxin B were assessed in megalin-shedding rats. The onset of nephrotoxicity was correlated with the daily dose of polymyxin B. Renal polymyxin B concentrations were found to be 3.6 ± 0.4 μg/g, 9.9 ± 1.5 μg/g, and 21.7 ± 4.8 μg/g in the 5-mg/kg, 10-mg/kg, and 20-mg/kg dosing groups, respectively. In megalin-shedding rats, the serum pharmacokinetics of polymyxin B remained unchanged, but the renal exposure was attenuated by 40% compared to that of control rats. The onset of polymyxin B-induced nephrotoxicity is correlated with the renal drug exposure. In addition, megalin appears to play a pivotal role in the renal accumulation of polymyxin B, which might contribute to nephrotoxicity.

[1]  E. Christensen,et al.  Role of megalin and cubilin in renal physiology and pathophysiology. , 2007, Reviews of physiology, biochemistry and pharmacology.

[2]  A. Saito,et al.  The Endocytic Receptor Megalin and its Associated Proteins in Proximal Tubule Epithelial Cells , 2014, Membranes.

[3]  V. Tam,et al.  Risk factors for nephrotoxicity onset associated with polymyxin B therapy. , 2015, The Journal of antimicrobial chemotherapy.

[4]  G. Forrest,et al.  Polymyxin antibiotics for gram-negative infections. , 2007, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[5]  J. Rastad,et al.  Tissue Distribution of Human gp330/Megalin, a Putative Ca2+-sensing Protein , 1997, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[6]  S. Moestrup,et al.  Evidence that epithelial glycoprotein 330/megalin mediates uptake of polybasic drugs. , 1995, The Journal of clinical investigation.

[7]  G. Turett,et al.  Polymyxin B Nephrotoxicity and Efficacy against Nosocomial Infections Caused by Multiresistant Gram-Negative Bacteria , 2003, Antimicrobial Agents and Chemotherapy.

[8]  M. Rowling,et al.  Vitamin D Transport Proteins Megalin and Disabled-2 Are Expressed in Prostate and Colon Epithelial Cells and Are Induced and Activated by All-Trans-Retinoic Acid , 2013, Nutrition and cancer.

[9]  L. Truong,et al.  Characterization of Polymyxin B Biodistribution and Disposition in an Animal Model , 2015, Antimicrobial Agents and Chemotherapy.

[10]  F. Luft,et al.  Megalin Deficiency Offers Protection from Renal Aminoglycoside Accumulation* , 2002, The Journal of Biological Chemistry.

[11]  A. Bonvin,et al.  Gentamicin Binds to the Megalin Receptor as a Competitive Inhibitor Using the Common Ligand Binding Motif of Complement Type Repeats , 2012, The Journal of Biological Chemistry.

[12]  Roger L. Nation,et al.  Polymyxin B Induces Apoptosis in Kidney Proximal Tubular Cells , 2013, Antimicrobial Agents and Chemotherapy.

[13]  V. Tam,et al.  Comparative Pharmacokinetic Profiling of Different Polymyxin B Components , 2016, Antimicrobial Agents and Chemotherapy.

[14]  Douglas Ferguson,et al.  Early prediction of polymyxin-induced nephrotoxicity with next-generation urinary kidney injury biomarkers. , 2014, Toxicological sciences : an official journal of the Society of Toxicology.

[15]  H. Yamaguchi,et al.  Megalin Contributes to Kidney Accumulation and Nephrotoxicity of Colistin , 2013, Antimicrobial Agents and Chemotherapy.

[16]  S. Moestrup,et al.  Renal tubule gp330 is a calcium binding receptor for endocytic uptake of protein. , 1992, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[17]  J. Li,et al.  Pharmacokinetics of intravenous polymyxin B in critically ill patients. , 2008, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[18]  S. Moestrup,et al.  Urinary megalin deficiency implicates abnormal tubular endocytic function in Fanconi syndrome. , 2002, Journal of the American Society of Nephrology : JASN.

[19]  V. Tam,et al.  In Vitro Assessment and Multicenter Cohort Study of Comparative Nephrotoxicity Rates Associated with Colistimethate versus Polymyxin B Therapy , 2014, Antimicrobial Agents and Chemotherapy.

[20]  M. Marzolo,et al.  New insights into the roles of megalin/LRP2 and the regulation of its functional expression. , 2011, Biological research.

[21]  E. Burdmann,et al.  Prevalence and Risk Factors for Acute Kidney Injury Associated with Parenteral Polymyxin B Use , 2009, The Annals of pharmacotherapy.

[22]  Ming Hu,et al.  Characterization of Polymyxin B-Induced Nephrotoxicity: Implications for Dosing Regimen Design , 2012, Antimicrobial Agents and Chemotherapy.

[23]  V. Tam,et al.  Pharmacokinetics and Renal Disposition of Polymyxin B in an Animal Model , 2012, Antimicrobial Agents and Chemotherapy.

[24]  K. Sekhri,et al.  To study the clinical efficacy and nephrotoxicity along with the risk factors for acute kidney injury associated with parenteral polymyxin B , 2013, Indian journal of critical care medicine : peer-reviewed, official publication of Indian Society of Critical Care Medicine.